文献速递基础与转化研究新药、器械与细胞基因治疗研发

从效应T细胞生成功能稳定且抗原特异性的Treg细胞用于炎症性疾病的细胞治疗

Generating functionally stable and antigen-specific Treg cells from effector T cells for cell therapy of inflammatory diseases.
PubMed 文献 · Sci Transl Med · 2025-10-22

研究通过抑制CDK8/19并在体外诱导过程中去除CD28共刺激,将小鼠和人的抗原及IL-2刺激的常规T细胞转化为高表达Foxp3的调节性T细胞,经间歇静息培养可高效转化naïve及效应/记忆CD4+ T细胞(包括TH1、TH2、TH17),所得iTreg细胞在转录和表观遗传上与nTreg相似且体内功能稳定,并在小鼠模型中有效抑制炎症性肠病和移植物抗宿主病。

要点

  • 抑制CDK8/19并去除CD28共刺激可在体外将抗原和IL-2刺激的Tconv细胞转化为高表达Foxp3的iTreg细胞。
  • 间歇静息培养可高效转化naïve及效应/记忆CD4+ T细胞(包括TH1、TH2、TH17)为Foxp3+ iTreg细胞。
  • 所得iTreg细胞在转录和表观遗传上与nTreg相似,体内功能和表型稳定,并在小鼠模型中抑制炎症性肠病和移植物抗宿主病。

核心结论

  • 采用效应/记忆Tconv细胞来源的功能稳定iTreg细胞进行过继细胞治疗,可能是实现抗原和疾病特异性治疗免疫性疾病的一种策略。

研究设计与样本

  • 体外研究:在小鼠和人类中,通过抑制CDK8/19并在体外Treg细胞诱导过程中去除CD28共刺激,将抗原和IL-2刺激的Tconv细胞转化为Foxp3+ Treg细胞。
  • 采用含IL-2的间歇静息培养重复诱导过程,转化naïve及效应/记忆CD4+ Tconv细胞(包括TH1、TH2、TH17)。
  • 在小鼠模型中评估iTreg细胞对炎症性肠病和移植物抗宿主病的抑制作用。

主要发现

  • 抑制CDK8/19可在抗原和IL-2刺激的Tconv细胞中诱导高Foxp3表达。
  • 去除CD28共刺激可建立Treg细胞特异性表观遗传改变,特异性促进Treg细胞特征基因尤其是Foxp3的表达。
  • 间歇静息培养可高效转化naïve及效应/记忆CD4+ Tconv细胞(包括TH1、TH2、TH17)为Foxp3+ Treg细胞。
  • iTreg细胞在转录和表观遗传修饰上与nTreg细胞相似,并在体内功能和表型稳定。
  • iTreg细胞在小鼠模型中有效抑制炎症性肠病和移植物抗宿主病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (Tconv) cells into Foxp3+ regulatory T (Treg) cells that are as stably suppressive as naturally occurring Treg (nTreg) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)-stimulated Tconv cells by CDK8/19 inhibition. We further established Treg cell-specific epigenetic changes by depriving CD28 costimulation during in vitro Treg cell induction to specifically promote the expression of Treg cell signature genes, especially Foxp3. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4+ Tconv cells, including T helper 1 (TH1), TH2, and TH17 cells, into Foxp3+ Treg cells. These induced Treg (iTreg) cells were similar to nTreg cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory Tconv cell-derived, functionally stable, iTreg cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Mikami N, Kawakami R, Sugimoto A, et al. Generating functionally stable and antigen-specific Treg cells from effector T cells for cell therapy of inflammatory diseases. Sci Transl Med. 2025. PMID: 41124283. doi:10.1126/scitranslmed.adr6049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。